Boston, MA 10/07/2014 (wallstreetpr) – Pharmaceuticals Inc (NASDAQ:REGN) disclosed that it received the Food and Drug Administration’s approval for its EYELEA injection for Macular Edema treatment after Retinal Vein Occlusion or RVO indication.
The company said that patients achieved a 17.0 letter mean improvement with EYLEA injection over the baseline in best-corrected visual acuity or BCVA. This is in comparison with a 6.9 letter mean improvement under the key secondary endpoint.
Dosage
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) said that the recommended dosage for patients affected by Macular Edema after RVO was 2 milligrams every month or four weeks. The company stated that it was fully committed to studying EYLEA for several VEGF-driven retinal diseases treatment.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) said that RVO was an important source of vision impairment in America. The expanded indications in all forms of RVO would offer a key treatment choice for the specialists of retina, as well as, their patients.
RVO was considered as the most frequent retinal vascular disease. The company indicated that it would happen whenever there was an obstacle in the retina’s vein, which was a light-sensitive nerve tissue. The obstruction results in a backup of blood besides leading to weak blood supply around the affected retina. As a result, Vascular Endothelial Growth Factor or VEGF gets released. VEGFT is a naturally occurring protein in blood vessels causing the patients to become leaky.
Injection Availability
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) disclosed that EYLEA would be available as an injection for every approved indication. The injection was given approval for the Macular Edema following RVO, Wet AMD and DME treatment in the United States.
Similarly, in the European Union and other countries, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) indicated that EYLEA was approved for Wet AMD, as well as, DME and Macular Edema following CRVO treatment. The company indicated that regulatory submissions were made in the EU and other countries for EYLEA for Macular Edema following BRVO.
